PolarityTE — Investor Presentation (November 2019)
39 slides from PolarityTE's investor presentation, Nov 20, 2019
Slide 1: PolarityTE: Where Self Regenerates Self
PolarityTE" Where Self Regenerates Self”
Slide 2: Forward-Looking Statement
PolarityTE here Se Regents Se Forward-Looking Statement This presentation contains forward-looking statements and projections. PolarityTE, Inc,, (the Company") makes no express or implied representation or warrant as to the completeness of this information or, in the case of projections, as to their
Slide 3: About PolarityTE, Inc.
About PolarityTE, Inc. A biotechnology company focused on transforming the lives of patients. * We use a patient's own cells to generate new tissue. * State of the art research facility to develop products based on our platform technology * Centralized manufacturing facility based in Salt Lake City,
Slide 4: Company History
= PolarityTE" ce) First patent application filed jae = bag og Formosa fire e PolarityTe Company formed Company History SkinTE SkinTE registered with FDA Lab established at Research Park First patient treated with SkinTE 40f31 IBEX Pre-clinical CRO acquired = 2018 © Ce) (@) Te) OsteolE OsteoTE regist
Slide 5: SkinTE Technology
SkinTE Technology PolarityTE manufactures products that take advantage of innate cellular micro-aggregates which contain progenitor cells that maintain the ability to regenerate structural tissues
Slide 6: How to Use SkinTE
How to Use SkinTE SkinTE * First FDA-registered product capable of regenerating functionally normal skin * Shown to regenerate full thickness skin with all layers (epidermis, dermis and hypodermis) and appendages (hair follicles and sebaceous glands) * SkinTE has produced function (sensation, sweat
Slide 7: SkinTE: Fully Functional, Full-Thickness Skin Product
SkinTE: Fully Functional, Full-Thickness Skin Product Real Skin Matters Skin is much more than a single layer of cells providing a barrier—skin is the largest organ of the human body and requires regeneration of all components for normal function. * Sensation * Immunity * Sweating + Sebum * Hair gro
Slide 8: Current Treatment Options
Current Treatment Options Scaffolds & Matrices—No Cells + Lacklliving cells + Limited ability to regenerate tissue + Typically require secondary coverage with skin grafts PolarityTE Where Se Regents Sof Allogeneic/Xenogeneic Cells & Tissues Risk of immune system rejection of foreign cells and tissue
Slide 9: Split-Thickness Skin Graft Donor Sites
Split-Thickness Skin Graft Donor Sites Split-Thickness Skin Graft Harvesting Skin Graft Donor Site After 2 Years Following Harvest @rxie
Slide 10: SkinTE Regenerates Functional Skin
SkinTE Regenerates Functional Skin SkinTE Applied to Chronic Wound on Right Lower Extremity (RLE) After Two Years of Failed Treatments Right Leg: Right Leg: Left Leg: Before SkinTE After SkinTE STSG Multi-Modality Imaging of Hair Follicles Confocal Confocal o E — 3 Merge Dual ESEM Stereoscopic £ & «
Slide 11: SkinTE Treats a Broad Spectrum of Wounds
SkinTE Treats a Broad Spectrum of Wounds SkinTE Applied to a Diabetic Foot Ulcer SkinTE Applied to a Venous Leg Ulcer ng: ee + Pretreatment ~8 weeks after a single application of SkinTE Pre-treatment ~7 weeks durability follow-up (Closed 22 days after single application of SkinTE) 11 of 31
Slide 12: SkinTE Treats a Broad Spectrum of Wounds
SkinTE Treats a Broad Spectrum of Wounds Venous Leg Ulcer Initial Wound ~7 weeks after single ~9 weeks after single Initial wound ~13 weeks after single application of SkinTE application of SkinTE application of SkinTE Chronic Wound Acute Wound Initial wound ~6 months after single application of Ski
Slide 13: SkinTE Treats a Broad Spectrum of Wounds
SkinTE Treats a Broad Spectrum of Wounds Pressure Sores — Sacral Ulcer Traumatic Injury - Lawnmower Accident Initial wound ~9 weeks after single 24 weeks after single Initial wound ~14 weeks after single application of SkinTE application of SkinTE application of SkinTE Traumatic Injury - Motor Vehic
Slide 14: SkinTE Treats a Broad Spectrum of Wounds
SkinTE Treats a Broad Spectrum of Wounds Chronic Recurring Wound Burn Reconstruction Initial wound ~11 weeks after single ~24 weeks after single Post-debridement ~13 months after single application of SkinTE application of SkinTE application of SkinTE Amputation Wound Post-Mohs Reconstruction v Pre-
Slide 15: SkinTE Clinical Trials in Chronic Wounds
SkinTE Clinical Trials in Chronic Wounds DFU Pilot VLU Pilot DFU RCT is VLU RCT ——P> Pressure Ulcer Study description Study Size Primary endpoint Enrollment Status Status/ Outcomes 1 Multicenter, randomized controlled trial 102 patients Percentage of ulcers closed Actively enrolling + Interim analys
Slide 16: SkinTE Pilot Trial Results
SkinTE Pilot Trial Results Diabetic Foot Ulcer (DFU) Pilot Trial Results presented at the Diabetic Limb Salvage Conference and the Symposium on Advanced Wound Care and The American Diabetes Association * 10 of 11 (90.9%) DFUs healed within 8 weeks of a single application of SkinTE + Median time to c
Slide 17: SkinTE Clinical Trial in Traumatic Wounds
SkinTE Clinical Trial in Traumatic Wounds : Prospective Lower Extremity == == == == == == == == == SkinTE Clinical Trials in Burn Wounds Enrolling Interim Complete Reporting Head-To-Head Burn a Prospective Burn ——> ===> Generated TD . * == == ==> Next 12 Months PolarityTE here Peers Se 17 of 31
Slide 18: Scientific Recognition
Scientific Recognition + Peer Reviewed Publication in international Wound Journal + Peer Reviewed Publication in Clinical Case Reports + Peer Reviewed Publication in Plastic Surgery Case Studies (in press) * 64 SkinTE abstracts accepted for presentation at healthcare, scientific and clinical confere
Slide 19: Defining the US Market
Defining the US Market Venous Leg Ulcers (VLUs) Diabetic Foot Ulcers (DFUs) Pressure Ulcers (PUs) Prevalence 600k Prevalence Prevalence 30.3mm 2.5mm ~670k ~1.0-2.5mm. Prevalence of Venous Ulcers ; ; Estimated Number of Individuals to 1 inthe United states I Feople in the U.S. with Diabetes WW pevelo
Slide 20: Defining the US Market
Defining the US Market Burns Incidence 486k | Burn Injuries Receiving Medical Tratment (FY15) Hi Yearly Hospitalizations Related to Burn Injury PolarityTE Dehiscence: “The separation of a surgical hee Se eps Sa incision or rupture of a wound closure” Wounds From Surgical Procedures Incidence Number
Slide 21: SkinTE Commercialization
SkinTE Commercialization Preclinical Proof Of Concept SkinTE , Autologous Homologous Skin Construct 2018 Limited Market Release 2019 Regional Market Release > 2020 Full National Release Chronic Wounds: Advance clinical evidence Trauma Wounds: Increase market awareness Burn Wounds: Work with thought
Slide 22: SkinTE Was Designed to Reduce Barriers and Increase Availability
SkinTE Was Designed to Reduce Barriers and Increase Availability of Regenerative Treatments Broad Utilization: * Surgeons * Medical Doctors Podiatrists + Physicians Assistants Nurses/Nurse Practitioners Broad Applications To Date: + Acute wounds * Chronic wounds + Traumatic injuries + Acute burns *
Slide 23: Reimbursement
Reimbursement Hospital Inpatient: Outpatient Settings: Physician Office: + Bundled DRG payments * Bundled facility payments * Procedure and product payments 23 of 31
Slide 24: Pipeline
Pipeline Preclinical > Proof Of Concept ¥ Trial SkinTE Cryo ete Cryopreserved SkinTE > SkinTE Point of Care —=—> ======> Point of Care SkinTE Device PTE 11000 —-----—> Bioactive Dressing ==> Generated TD == == => Next 12 Months 24 of 31
Slide 25: Post OsteoTE
Post OsteoTE OsteoTE” Registered with the FDA in 2018 Load-Displacement Biomechanical Testing A Load (N) (a Defect Control DBM + BMP2 *Pre-Clinical _ PolarityTE
Slide 26: Financial Snapshot
Financial Snapshot * Cash, cash equivalents and short-term investments were $45.9 million as of September 30, 2019 * ~27M shares outstanding as of November 8, 2019 * Products segment achieved 62.5% gross profit margin in 3Q 2019 primarilydue toa reduction in direct manufacturing costs* Products Gros
Slide 27: Management Team
Management Team Office of the Chief Executive Paul Mann, CFA, MEng, MA (Cantab) Chief Financial Officer David Seaburg President ~~ Richard Hague W f chlefoperating.omiee Stephen Milner, MD, Edward Swanson, MD DDS, DSc, FACS Chief Translational Medicine Chief Clinical Officer Officer & Co-Founder Nik
Slide 28: Board of Directors
PolarityTE Board of Directors Peter Cohen, MBA Chairman of the Board + Former Board Member of the NYSE “+ Former Chairman of Shearson Lehman Hutton, Inc + Former Chairman and CEO of Cowen inc. + Vice Chairman and Lead Director of the Board of Directors of Scientific Games Corporation + Federal Reser
Slide 29: Welcome to the Shift
Welcome to the Shift PolarityTE Corporate PolarityTE Investor Relations www.PolarityTE.com Rich Haerle, MBA, MPH [email protected] VP of Investor Relations Corporate Inquiries: (800) 378-2694 IR Inquiries: (385) 237-5786 [email protected] [email protected] Nasdaq; PTE 29 o
Slide 30: Appendix
Appendix
Slide 31: SkinTE: FDA Registered Through HCT/P Pathway
here Peers Se A2 of A10 SkinTE: FDA Registered Through 361 HCT/P Pathway + Minimally manipulated * Autologous - from the patient, for the patient * Homologous - skin for skin + Manufacture must not involve combination with another article, except for water, crystalloids or a sterilizing, preserving
Slide 32: Where Skin Grafts Fail
Where Skin Grafts Fail SkinTE Following Replacement of Split-Thickness Skin Graft in Fibrotic Wound Bed Excision of skin graft 2weeks post-op 4 Weeks Post-Op Conducting pinch test of SkinTE at 6 months Punch biopsy of SkinTE- regenerated skin depicts all layers of full-thickness skin and appendages
Slide 33: Chronic Wound
Chronic Wound SkinTE Applied to Chronic Wound on Right Lower Extremity (RLE) After Two Years of Failed Treatments 2-year-old chronic refractory wound on right lower extremity Right lower extremity 2-year-old previously ~12 weeks after single placed skin graft on left application of SkinTE lower extr
Slide 34: Patient Experience
Patient Experience “If [had to choose between SkinTE and another skin graft, | would choose SkinTE every time, because it is actually working, and you do not have a huge area of healthy skin removed that also then needs to heal, like with traditional skin grafts.” —Devon, a SkinTE Patient Breaiiyt |
Slide 35: Feedback from Patients, Providers and Thought-Leaders
Feedback from Patients, Providers and Thought-Leaders “My skin is smooth. The ir is actually growing back. It doesn't itch.” —Natasha, Burn Survivor and SkinTE Patient The science and clinical application of regenerative products is a major emphasis at SkinTE in a variety of cli e a skin that functi
Slide 36: Poster #CS-03
Poster #CS-03 Closure of refractory diabetic foot ulcers and venous stasis leg ulcers using a single application of an fe) autologous homologous skin construct in the clinic setting Center of USC |FAny David G. Armstrong!, Dennis Orgill*, Robert Galiano*, Paul Glat®, Charles M. Zelen® | Southwestern
Slide 37: Poster #45-LB
Poster #45-LB Late Breaking: Results of a Pilot Evaluation of a Novel Autologous Homologous Skin Construct Treatment of Diabetic Foot Wounds eae is to Commenters! Treatments 4 a A ng'*, Dennis Orgill?, harles no | Introduction ow for Clinic Setting 2 fe Case #01: DFU of Left Foot (1c a E of Results
Slide 38: Poster #CS-001
Poster #CS-001 A 1 Soutvestem Academic Limb Salvage Alliance (SALSA), Los Angeles, CA; 2 Keck Schoo! of Medicine, University of Sothera Califia, Los Angeles, CA; 3 Division of Pati Surgery, Brigham and Women's Hospital, Boston, MA; Venous Stasis Leg Ulcers David G. Armstrong!, Dennis Orgill, Robert
Slide 39: About SkinTE
About SkinTE™ SkinTE is a human cellular and tissue-based product derived from a patient's own skin (autologous) intended for the repair, reconstruction, and replacement of skin tissue. SkinTE is intended to be used by medical professionals for homologous uses of skin tissues/integument. Aseptic sur